zentaris.com (AEZS) Quarterly EPS earnings growth

Symbol and logo of brand zentaris.com (AEZS)

Aeterna Zentaris (AEZS) is expanding its network of partner clinics through licensing deals in the mature diagnostics market. The quarterly EPS growth rate on this chart clearly demonstrates the financial dynamics, where the current metric equals 0.00. Revenues are based on Macrilen test sales and royalties. Stable demand for specialized studies makes this defensive business resilient to economic fluctuations.

AEZS: Aeterna Zentaris Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 08/17/2024

zentaris.com (AEZS) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Aeterna Zentaris
Flagship merchandise of Aeterna Zentaris

Investors assess capital risks through net income dynamics, where any deviation from the trend signals potential volatility. For Aeterna Zentaris (AEZS), which focuses on the commercialization of tests and endocrinology developments, the quarterly EPS growth rate measures the speed of change in earnings per share, allowing for the identification of business value growth phases and the probability of generating alpha during an upward trend.

Who Aeterna Zentaris competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Abeona Therapeutics, Inc. (ABEO)|Year-over-year net earnings per share growth for the last 12 months Mereo BioPharma Group plc MREO|Year-over-year earnings per share growth for the last twelve months Protalix BioTherapeutics PLX|Quarterly EPS earnings growth Pliant Therapeutics PLRX|appliedtherapeutics.com - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months RNTX (Rein Therapeutics, Inc.)|GELS: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months SRXH (SRx Health Solutions)|Year-over-year net earnings per share growth for the last 12 months PLRZ (Polyrizon Ltd)|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth